Arvinas Shares Sink After Breast Cancer Treatment Didn't Improve Survival in Intent-to-Treat Population

Dow Jones

2025/06/02

By Connor Hart

Shares of Arvinas fell after the company said its in-development treatment for breast cancer didn't reach statistical significance in improving progression-free survival for its intent-to-treat population.

The stock declined 9.7%, to $6.50, in pre-market trading Monday. Shares ended Friday's regular session 4% lower, at $7.20, having lost about three-quarters of their value in the past year.

The biotechnology said that the therapy, vepdegestrant, notched a progression-free survival rate of 3.7 months in a recent Phase 3 study, compared with a progression-free survival rate of 3.6 months for fulvestrant, an existing breast cancer treatment.

Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that the therapy did demonstrate a meaningful improvement in progression-free survival among estrogen receptor 1 mutation patients.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

June 02, 2025 07:16 ET (11:16 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540767942"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540767942\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540767942?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 19:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540767942","market":"sg","top_or_hot":-1,"title":"Arvinas Shares Sink After Breast Cancer Treatment Didn't Improve Survival in Intent-to-Treat Population","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Arvinas fell after the company said its in-development treatment for breast cancer didn't reach statistical significance in improving progression-free survival for its intent-to-treat population. \n</p>\n<p>\n  The stock declined 9.7%, to $6.50, in pre-market trading Monday. Shares ended Friday's regular session 4% lower, at $7.20, having lost about three-quarters of their value in the past year. \n</p>\n<p>\n  The biotechnology said that the therapy, vepdegestrant, notched a progression-free survival rate of 3.7 months in a recent Phase 3 study, compared with a progression-free survival rate of 3.6 months for fulvestrant, an existing breast cancer treatment. \n</p>\n<p>\n  Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that the therapy did demonstrate a meaningful improvement in progression-free survival among estrogen receptor 1 mutation patients. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 02, 2025 07:16 ET (11:16 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arvinas Shares Sink After Breast Cancer Treatment Didn't Improve Survival in Intent-to-Treat Population</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArvinas Shares Sink After Breast Cancer Treatment Didn't Improve Survival in Intent-to-Treat Population\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-06-02 19:16</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Arvinas fell after the company said its in-development treatment for breast cancer didn't reach statistical significance in improving progression-free survival for its intent-to-treat population. \n</p>\n<p>\n  The stock declined 9.7%, to $6.50, in pre-market trading Monday. Shares ended Friday's regular session 4% lower, at $7.20, having lost about three-quarters of their value in the past year. \n</p>\n<p>\n  The biotechnology said that the therapy, vepdegestrant, notched a progression-free survival rate of 3.7 months in a recent Phase 3 study, compared with a progression-free survival rate of 3.6 months for fulvestrant, an existing breast cancer treatment. \n</p>\n<p>\n  Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that the therapy did demonstrate a meaningful improvement in progression-free survival among estrogen receptor 1 mutation patients. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 02, 2025 07:16 ET (11:16 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1023059063.AUD","symbol_name":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2540767942","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540767942","pubTimestamp":1748862960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Arvinas fell after the company said its in-development treatment for breast cancer didn't reach statistical significance in improving progression-free survival for its intent-to-treat population.The stock declined 9.7%, to $6.50, in pre-market trading Monday. Shares ended Friday's regular session 4% lower, at $7.20, having lost about three-quarters of their value in the past year.The biotechnology said that the therapy, vepdegestrant, notched a progression-free survival rate of 3.7 months in a recent Phase 3 study, compared with a progression-free survival rate of 3.6 months for fulvestrant, an existing breast cancer treatment.Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that the therapy did demonstrate a meaningful improvement in progression-free survival among estrogen receptor 1 mutation patients.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4592":"伊斯兰概念","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","ARVN":"Arvinas Holding Company LLC","BK4568":"美国抗疫概念","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4588":"碎股","BK4550":"红杉资本持仓","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4007":"制药","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4581":"高盛持仓","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4599":"减肥药","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF"},"translate_title":"乳腺癌治疗未能提高意向治疗人群的生存率后，Arvinas股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARVN":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Arvinas fell after the company said its in-development treatment for breast cancer didn't reach statistical significance in improving progression-free survival for its intent-to-treat population. \n\n\n  The stock declined 9.7%, to $6.50, in pre-market trading Monday. Shares ended Friday's regular session 4% lower, at $7.20, having lost about three-quarters of their value in the past year. \n\n\n  The biotechnology said that the therapy, vepdegestrant, notched a progression-free survival rate of 3.7 months in a recent Phase 3 study, compared with a progression-free survival rate of 3.6 months for fulvestrant, an existing breast cancer treatment. \n\n\n  Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that the therapy did demonstrate a meaningful improvement in progression-free survival among estrogen receptor 1 mutation patients. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 02, 2025 07:16 ET (11:16 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}